Bone-marrow relapse in paediatric acute lymphoblastic leukaemia

Area of Science:

• Hematology
• Pediatric Oncology
• Leukemia Research

Background:

• Marrow relapse is a primary barrier to curing acute lymphoblastic leukemia (ALL) in 10-15% of young patients.
• Minimal residual disease biology suggests early relapses stem from initial diagnostic residual cells, while late relapses may arise from new mutations.
• Current treatments for marrow relapse, including intensified chemotherapy and stem cell transplantation, show limited improvement over two decades.

Purpose of the Study:

• To review the challenges and current outcomes of treating marrow relapse in acute lymphoblastic leukemia.
• To discuss the biological basis of early versus late relapses in ALL.
• To explore potential avenues for improving risk stratification and developing novel therapies for pediatric ALL.

Main Methods:

• Review of existing literature on acute lymphoblastic leukemia marrow relapse.
• Analysis of treatment strategies including chemotherapy and hematopoietic stem cell transplantation.
• Discussion of the biological mechanisms underlying ALL relapse.

Main Results:

• Hematopoietic stem cell transplantation appears superior to continuation chemotherapy for early marrow relapse.
• Current therapies achieve a 10% cure rate for early relapses and 50% for late relapses.
• Outcomes for marrow relapse in ALL have seen minimal improvement over the past 20 years.

Conclusions:

• Understanding the molecular biology of ALL is crucial for developing better risk stratification and novel treatments.
• There is a need for improved drugs and innovative clinical trial designs for pediatric ALL.
• Expediting the development and testing of new therapies is essential to improve cure rates for relapsed ALL.